Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2371-2378

  Chou, Sunwen ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; VIRUS ENZYME;

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CONTROLLED STUDY; HUMAN CYTOMEGALOVIRUS; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS RESISTANCE; VIRUS STRAIN;

ANTIVIRAL AGENTS; BASE SEQUENCE; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CLONING, MOLECULAR; CYTOMEGALOVIRUS; DNA PRIMERS; DRUG RESISTANCE, VIRAL; GANCICLOVIR; GENES, VIRAL; GENETIC VARIATION; HUMANS; MUTAGENESIS; PHENOTYPE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RECOMBINATION, GENETIC;

EID: 77952596450     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00186-10     Document Type: Article

References (35)

1. Abraham, B., S. Lastere, J. Reynes, F. Bibollet-Ruche, N. Vidal, and M. Segondy. 1999. Ganciclovir resistance and UL97 gene mutations in cytomegalovirus blood isolates from patients with AIDS treated with ganciclovir. J. Clin. Virol. 13:141-148.
2. Baldanti, F., D. Michel, L. Simoncini, M. Heuschmid, A. Zimmermann, R. Minisini, P. Schaarschmidt, T. Schmid, G. Gerna, and T. Mertens. 2002. Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. Antiviral Res. 54:59-67. (Pubitemid 34219175)
3. Boivin, G., C. Gilbert, A. Gaudreau, I. Greenfield, R. Sudlow, and N. A. Roberts. 2001. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J. Infect. Dis. 184:1598-1602.
4. Borst, E. M., G. Hahn, U. H. Koszinowski, and M. Messerle. 1999. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol. 73:8320-8329.
5. Castor, J., L. Cook, L. Corey, and K. R. Jerome. 2007. Rapid detection directly from patient serum samples of human cytomegalovirus UL97 mutations conferring ganciclovir resistance. J. Clin. Microbiol. 45:2681-2683.
6. Chou, S. 2008. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 18:233-246.
7. Chou, S., A. Erice, M. C. Jordan, G. M. Vercellotti, K. R. Michels, C. L. Talarico, S. C. Stanat, and K. K. Biron. 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171:576-583.
8. Chou, S., G. Marousek, S. Guentzel, S. E. Follansbee, M. E. Poscher, J. P. Lalezari, R. C. Miner, and W. L. Drew. 1997. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 176:786-789.
9. Chou, S., G. Marousek, S. Li, and A. Weinberg. 2008. Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. J. Clin. Virol. 43:107-109.
10. Chou, S., L. C. Van Wechel, H. M. Lichy, and G. I. Marousek. 2005. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob. Agents Chemother. 49: 2710-2715.
11. Chou, S., L. C. Van Wechel, and G. I. Marousek. 2007. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J. Infect. Dis. 196: 91-94.
12. Chou, S., R. H. Waldemer, A. E. Senters, K. S. Michels, G. W. Kemble, R. C. Miner, and W. L. Drew. 2002. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J. Infect. Dis. 185:162-169.
13. Cihlar, T., M. D. Fuller, and J. M. Cherrington. 1998. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from over-lapping DNA fragments. J. Virol. 72:5927-5936. (Pubitemid 28283381)
14. Erice, A., N. Borrell, W. Li, W. J. Miller, and H. H. Balfour, Jr. 1998. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J. Infect. Dis. 178:531-534.
15. Faizi Khan, R., S. Mori, Y. Eizuru, K. Kumura Ishii, and Y. Minamishima. 1998. Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant. Antiviral Res. 40:95-103. (Pubitemid 28535175)
16. Gilbert, C., J. Bestman-Smith, and G. Boivin. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updat. 5:88-114.
17. Gilbert, C., and G. Boivin. 2005. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49:873-883.
18. Hanks, S. K., A. M. Quinn, and T. Hunter. 1988. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241:42-52.
19. Hirt, B. 1967. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26:365-369.
20. Humar, A., D. Kumar, J. Preiksaitis, G. Boivin, D. Siegal, J. Fenton, K. Jackson, S. Nia, and D. Lien. 2005. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am. J. Transplant. 5:1462-1468.
21. Iwasenko, J. M., G. M. Scott, W. D. Rawlinson, A. Keogh, D. Mitchell, and S. Chou. 2009. Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D. J. Med. Virol. 81:507-510.
22. Jabs, D. A., B. K. Martin, M. S. Forman, J. P. Dunn, J. L. Davis, D. V. Weinberg, K. K. Biron, and F. Baldanti. 2001. Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J. Infect. Dis. 183:333-337.
23. Limaye, A. P., L. Corey, D. M. Koelle, C. L. Davis, and M. Boeckh. 2000. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356:645-649. (Pubitemid 30627592)
24. Lurain, N. S., S. M. Bhorade, K. J. Pursell, R. K. Avery, V. V. Yeldandi, C. M. Isada, E. S. Robert, D. J. Kohn, M. Q. Arens, E. R. Garrity, A. J. Taege, M. G. Mullen, K. M. Todd, J. W. Bremer, and B. Yen-Lieberman. 2002. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J. Infect. Dis. 186:760-768.
25. Lurain, N. S., L. E. Spafford, and K. D. Thompson. 1994. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J. Virol. 68:4427-4431.
26. Lurain, N. S., A. Weinberg, C. S. Crumpacker, and S. Chou. 2001. Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob. Agents Chemother. 45:2775-2780.
27. Martin, M., C. Gilbert, E. Covington, and G. Boivin. 2006. Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. J. Infect. Dis. 194: 579-583.
28. Martin, M., N. Goyette, J. Ives, and G. Boivin. 2010. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. J. Clin. Virol. 47:321-324.
29. Michel, D., P. Schaarschmidt, K. Wunderlich, M. Heuschmid, L. Simoncini, D. Muhlberger, A. Zimmermann, I. Pavic, and T. Mertens. 1998. Functional regions of the human cytomegalovirus protein pUL97 involved in nuclear localization and phosphorylation of ganciclovir and pUL97 itself. J. Gen. Virol. 79:2105-2112.
30. Prichard, M. N. 2009. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev. Med. Virol. 19:215-229.
31. Reddy, A. J., A. K. Zaas, K. E. Hanson, and S. M. Palmer. 2007. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. J. Heart Lung Transplant. 26:1286-1292.
32. Smith, I. L., J. M. Cherrington, R. E. Jiles, M. D. Fuller, W. R. Freeman, and S. A. Spector. 1997. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176:69-77.
33. Spector, S. A., K. Hsia, D. Wolf, M. Shinkai, and I. Smith. 1995. Molecular detection of human cytomegalovirus and determination of genotypic ganciclovir resistance in clinical specimens. Clin. Infect. Dis. 21(Suppl. 2):S170-S173.
34. Warming, S., N. Costantino, D. L. Court, N. A. Jenkins, and N. G. Copeland. 2005. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 33:e36.
35. Wolf, D. G., I. L. Smith, D. J. Lee, W. R. Freeman, M. Flores-Aguilar, and S. A. Spector. 1995. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J. Clin. Invest. 95:257-263.